AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11960302 — intervention group
Group type: COMPARATOR
Intervention: Energy-restricted diet plan of 5.2-6.3 MJ/day without nutrient-fortified liquid meal replacement for group A.
Number of subjects: 100
Study 11960302 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy-restricted diet plan of 5.2-6.3 MJ/day with MR for group B.
Number of subjects: 100
Study 11960302 — intervention group
Group type: COMPARATOR
Intervention: Energy-restricted diet plan of 5.2-6.3 MJ/day without MR for group A.
Number of subjects: 100
Study 10215730 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 75 mg
Number of subjects: 284
Study 10215730 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 284
Study 8846749 — intervention group
Group type: EXPERIMENTAL
Intervention: L-propionyl carnitine (2 g by slow infusion b.i.d, plus heparin and buflomedil)
Number of subjects: 12
Study 8846749 — intervention group
Group type: COMPARATOR
Intervention: Placebo (plus heparin and buflomedil)
Number of subjects: 12
Study 2361811 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate duration exercise (M‐EX)
Number of subjects: 12
Study 2361811 — intervention group
Group type: EXPERIMENTAL
Intervention: Long duration exercise (L‐EX)
Number of subjects: 12
Study 2361811 — intervention group
Group type: COMPARATOR
Intervention: No exercise (NO‐EX)
Number of subjects: 12
Study 389824 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacampicillin 400 mg plus 1 g probenecid
Number of subjects: 883
Study 389824 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacampicillin 800 mg plus 1 g probenecid
Number of subjects: 883
Study 389824 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacampicillin 1600 mg plus 1 g probenecid
Number of subjects: 883
Study 389824 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacampicillin (all doses)
Number of subjects: 883
Study 389824 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacampicillin 1600 mg
Number of subjects: 883
Study 31918929 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold (BVS)
Number of subjects: 400
Study 31918929 — intervention group
Group type: COMPARATOR
Intervention: Cobalt-chromium everolimus-eluting stent
Number of subjects: 400
Study 30984998 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Anesthesia (SA)
Number of subjects: 100
Study 30984998 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 100
Study 26187147 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS treatment (10Hz for 3 weeks)
Number of subjects: 24
Study 26187147 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS treatment
Number of subjects: 24
Study 26187147 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS treatment
Number of subjects: 24
Study 23039313 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-completed nutrition screening
Number of subjects: 81
Study 23039313 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nurse-completed nutrition screening)
Number of subjects: 81
Study 23039313 — intervention group
Group type: EXPERIMENTAL
Intervention: Referred patients
Number of subjects: 81
Study 23039313 — intervention group
Group type: COMPARATOR
Intervention: Non-referred patients
Number of subjects: 81
Study 21823783 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 73
Study 21823783 — intervention group
Group type: COMPARATOR
Intervention: Stress Management Training
Number of subjects: 73
Study 19134532 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 885
Study 19134532 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine microemulsion
Number of subjects: 885
Study 19134532 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus and Cyclosporine microemulsion
Number of subjects: 885
Study 16999746 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized clinical trial designed to reduce HIV sexual risk behavior
Number of subjects: 106
Study 12630982 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine treatment (n = 54)
Number of subjects: 191
Study 12630982 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group (n = 56)
Number of subjects: 191
Study 12630982 — intervention group
Group type: COMPARATOR
Intervention: Mood disorder patients (n = 36)
Number of subjects: 191
Study 12630982 — intervention group
Group type: COMPARATOR
Intervention: Schizophrenics not treated with clozapine (n = 41)
Number of subjects: 191
Study 10715931 — intervention group
Group type: EXPERIMENTAL
Intervention: Power toothbrush (Braun Oral‐B Ultra Plaque Remover, Braun GmbH)
Number of subjects: 16903
Study 9379381 — intervention group
Group type: EXPERIMENTAL
Intervention: Healon GV
Number of subjects: 60
Study 9379381 — intervention group
Group type: COMPARATOR
Intervention: Healon
Number of subjects: 60
Study 1529284 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (10 g/day)
Number of subjects: 43
Study 1529284 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 43
Study 2868467 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic maintenance medication
Number of subjects: 0
Study 2868467 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroleptic crisis intervention
Number of subjects: 0
Study 2868467 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic early intervention
Number of subjects: 0
Study 31227284 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix 150 mg once a day
Number of subjects: 1298
Study 31227284 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix 200 mg twice a day
Number of subjects: 1298
Study 31227284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1298
Study 29950019 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalable randomized algorithm for estimating variance components in linear mixed models (LMMs)
Number of subjects: 500000
Study 29950019 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard hardware implementation of the proposed method
Number of subjects: 500000
Study 29394018 — intervention group
Group type: EXPERIMENTAL
Intervention: C‐T (cream applied with repeated toner every 2 h)
Number of subjects: 7
Study 29394018 — intervention group
Group type: EXPERIMENTAL
Intervention: C+T (cream and toner applied successively)
Number of subjects: 7
Study 29394018 — intervention group
Group type: EXPERIMENTAL
Intervention: T+C (toner and cream applied successively)
Number of subjects: 7
Study 29394018 — intervention group
Group type: COMPARATOR
Intervention: C (cream only)
Number of subjects: 7
Study 29394018 — intervention group
Group type: EXPERIMENTAL
Intervention: C‐S (cream applied with repeated spray water every 2 h)
Number of subjects: 7
Study 29394018 — intervention group
Group type: EXPERIMENTAL
Intervention: T‐T (toner applied with repeated toner every 2 h)
Number of subjects: 7
Study 29394018 — intervention group
Group type: COMPARATOR
Intervention: N (untreated group)
Number of subjects: 7
Study 24675035 — intervention group
Group type: EXPERIMENTAL
Intervention: Covered double-layered stent
Number of subjects: 134
Study 24675035 — intervention group
Group type: COMPARATOR
Intervention: Uncovered unfixed-cell braided stent
Number of subjects: 134
Study 23033520 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV antibody test
Number of subjects: 0
Study 23033520 — intervention group
Group type: COMPARATOR
Intervention: DNA polymerase chain reaction (PCR) testing
Number of subjects: 0
Study 19716013 — intervention group
Group type: EXPERIMENTAL
Intervention: MPH (microporous polysaccharide hemospheres)
Number of subjects: 40
Study 19716013 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated side)
Number of subjects: 40
Study 18089865 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine infusion over 100 minutes
Number of subjects: 33
Study 18089865 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine infusion over 30 minutes
Number of subjects: 33
Study 15329586 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment maneuver (sustained inflation of 50 cm H2O for 30 s)
Number of subjects: 30
Study 15329586 — intervention group
Group type: COMPARATOR
Intervention: Control group (no recruitment maneuver)
Number of subjects: 30
Study 19260180 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory model present
Number of subjects: 48
Study 19260180 — intervention group
Group type: COMPARATOR
Intervention: Auditory model absent
Number of subjects: 48
Study 9702852 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg of digoxin alone (Phase 1)
Number of subjects: 0
Study 9702852 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg of digoxin after 200 mg of acarbose (Phase 2)
Number of subjects: 0
Study 9702852 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg of digoxin after 100 mg of acarbose (Phase 3)
Number of subjects: 0
Study 7978671 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia
Number of subjects: 80
Study 7978671 — intervention group
Group type: COMPARATOR
Intervention: Spinal anesthesia
Number of subjects: 80
Study 2657105 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine hydrochloride (maximum of 42.0 mg orally daily)
Number of subjects: 82
Study 2657105 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 4938431 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa (maximum tolerated dosage)
Number of subjects: 21
Study 4938431 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa + L-alpha-methyldopahydrazine
Number of subjects: 21
Study 4938431 — intervention group
Group type: COMPARATOR
Intervention: Control (Levodopa alone)
Number of subjects: 21
Study 31432432 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 40
Study 31432432 — intervention group
Group type: COMPARATOR
Intervention: Light physical exercise
Number of subjects: 40
Study 29847672 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-04634817 200 mg once-daily (QD) plus placebo
Number of subjects: 199
Study 29847672 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab 0.3/0.5 mg monthly plus oral placebo
Number of subjects: 199
Study 28129746 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded Exercise Therapy (GET)
Number of subjects: 0
Study 28129746 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 0
Study 28129746 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 0
Study 26371113 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 11801
Study 26371113 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 11801
Study 23104718 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 145
Study 23104718 — intervention group
Group type: COMPARATOR
Intervention: Oral care education
Number of subjects: 145
Study 21664811 — intervention group
Group type: EXPERIMENTAL
Intervention: sorafenib 400mg bid
Number of subjects: 458
Study 21664811 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 458
Study 17414674 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine
Number of subjects: 1523
Study 17414674 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 1523
Study 15176768 — intervention group
Group type: EXPERIMENTAL
Intervention: Hallucination focused integrative treatment (HIT)
Number of subjects: 0
Study 15176768 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 0
Study 12487889 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous bone as orbital grafting material
Number of subjects: 21
Study 12487889 — intervention group
Group type: COMPARATOR
Intervention: HA composite material as orbital grafting material
Number of subjects: 21
Study 12487889 — intervention group
Group type: EXPERIMENTAL
Intervention: Late reconstruction of the orbit and reposition of the globe
Number of subjects: 21
Study 12487889 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention
Number of subjects: 21
Study 9806657 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment with carboplatin (600 mg/m2 on Day 1), cyclophosphamide (250 mg/m2 on Day 1), and cisplatin (100 mg/m2 on Day 8 every 4 weeks) with or without amifostine (740‐1140 mg/m2)
Number of subjects: 26
Study 9806657 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment with carboplatin, cyclophosphamide, and cisplatin
Number of subjects: 26
Study 7661678 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue
Number of subjects: 56
Study 7661678 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 56
Study 2679048 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10-30 mg before meals)
Number of subjects: 10
Study 2679048 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 10
Study 2679048 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 1008540 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole
Number of subjects: 0
Study 31888732 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication Therapy Management (MTM) intervention
Number of subjects: 90
Study 31888732 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 28210027 — intervention group
Group type: EXPERIMENTAL
Intervention: Klapp method (20 sessions, three times a week)
Number of subjects: 22
Study 28210027 — intervention group
Group type: COMPARATOR
Intervention: Inactive control group (no intervention)
Number of subjects: 22
Study 25872929 — intervention group
Group type: COMPARATOR
Intervention: Sham SM
Number of subjects: 216
Study 25872929 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilization
Number of subjects: 216
Study 25872929 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation
Number of subjects: 216
Study 23308171 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycemia (plasma glucose levels 14.1 ± 2.6 mM for T2D-HF)
Number of subjects: 18
Study 23308171 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycemia (plasma glucose levels 9.9 ± 2.1 mM for T2D-nonHF)
Number of subjects: 18
Study 23308171 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycemia
Number of subjects: 18
Study 23308171 — intervention group
Group type: COMPARATOR
Intervention: Normoglycemia
Number of subjects: 18
Study 21056926 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery after 5 years
Number of subjects: 255
Study 21056926 — intervention group
Group type: EXPERIMENTAL
Intervention: Employment or studying status after 5 years
Number of subjects: 255
Study 21056926 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of psychotic symptoms among those working
Number of subjects: 255
Study 21056926 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery predictors
Number of subjects: 255
Study 18371107 — intervention group
Group type: EXPERIMENTAL
Intervention: COPAD chemotherapy (cyclophosphamide, vincristine, prednisolone, and doxorubicin), given in two courses without intrathecal chemotherapy.
Number of subjects: 132
Study 16436174 — intervention group
Group type: EXPERIMENTAL
Intervention: Bath PUVA
Number of subjects: 8
Study 16436174 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral PUVA
Number of subjects: 8
Study 15452093 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycemia (15 mM blood glucose)
Number of subjects: 14
Study 15452093 — intervention group
Group type: COMPARATOR
Intervention: Euglycemia (5 mM blood glucose)
Number of subjects: 14
Study 11579649 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of rifampicin 600 mg plus ofloxacin 400 mg plus minocycline 100 mg (ROM) administered as single dose
Number of subjects: 236
Study 11579649 — intervention group
Group type: COMPARATOR
Intervention: Standard WHO/MDT/PB six months regimen
Number of subjects: 236
Study 9822485 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular dexamethasone (6 mg every 12 hours for 4 doses, repeated weekly until 34 weeks' gestation)
Number of subjects: 170
Study 9822485 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dexamethasone (8 mg every 12 hours for 4 doses, repeated weekly until 34 weeks' gestation)
Number of subjects: 170
Study 9822485 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dexamethasone
Number of subjects: 170
Study 7858362 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v.‐PCA ketorolac 5 mg/ml
Number of subjects: 70
Study 7858362 — intervention group
Group type: COMPARATOR
Intervention: i.v.‐PCA morphine 1 mg/ml
Number of subjects: 70
Study 2698170 — intervention group
Group type: EXPERIMENTAL
Intervention: PABA-serum concentration in patients with normal pancreatic function
Number of subjects: 0
Study 2698170 — intervention group
Group type: COMPARATOR
Intervention: PABA-serum concentration in patients with exocrine pancreatic insufficiency
Number of subjects: 0
Study 2698170 — intervention group
Group type: COMPARATOR
Intervention: Pharmacologic inhibition using pirenzepine
Number of subjects: 0
Study 2698170 — intervention group
Group type: COMPARATOR
Intervention: Urine-PABA concentrations in patients with exocrine pancreatic insufficiency
Number of subjects: 0
Study 1020533 — intervention group
Group type: EXPERIMENTAL
Intervention: Trichloroethylene (TCE) exposure at 100 ppm for 5 days
Number of subjects: 7
Study 1020533 — intervention group
Group type: COMPARATOR
Intervention: Placebo exposure
Number of subjects: 7
Study 30792143 — intervention group
Group type: COMPARATOR
Intervention: 2 g PS
Number of subjects: 72
Study 30792143 — intervention group
Group type: COMPARATOR
Intervention: 3 g OBG
Number of subjects: 72
Study 30792143 — intervention group
Group type: COMPARATOR
Intervention: 2 g PS and 3 g OBG
Number of subjects: 72
Study 30792143 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 72
Study 30221776 — intervention group
Group type: EXPERIMENTAL
Intervention: NIR t‐PBM
Number of subjects: 20
Study 30221776 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 20
Study 28640772 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate mouth rinse (25 ml of an 18% CHO solution)
Number of subjects: 12
Study 28640772 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo rinse
Number of subjects: 12
Study 28640772 — intervention group
Group type: COMPARATOR
Intervention: No-rinse control condition
Number of subjects: 12
Study 25880414 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led telephone health coaching
Number of subjects: 556
Study 25880414 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 556
Study 23865053 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorometholone/tetrahydrozoline
Number of subjects: 0
Study 23865053 — intervention group
Group type: COMPARATOR
Intervention: Fluorometholone
Number of subjects: 0
Study 23865053 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone
Number of subjects: 0
Study 21135733 — intervention group
Group type: EXPERIMENTAL
Intervention: Ictal SPECT
Number of subjects: 240
Study 21135733 — intervention group
Group type: COMPARATOR
Intervention: Non-SPECT
Number of subjects: 240
Study 19170716 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg) for 16 weeks
Number of subjects: 30
Study 19170716 — intervention group
Group type: EXPERIMENTAL
Intervention: Hirsute patients
Number of subjects: 30
Study 19170716 — intervention group
Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 30
Study 17309907 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease management programme delivered by specialist nurses trained in the management of patients with CHD and CHF
Number of subjects: 1316
Study 17309907 — intervention group
Group type: COMPARATOR
Intervention: Usual care delivered by the primary healthcare team
Number of subjects: 1316
Study 14996882 — intervention group
Group type: EXPERIMENTAL
Intervention: Handheld computer documentation
Number of subjects: 78
Study 14996882 — intervention group
Group type: COMPARATOR
Intervention: Conventional paper documentation
Number of subjects: 78
Study 11321192 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (oGA) for 2,433 +/- 59 days
Number of subjects: 208
Study 11321192 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oPBO) followed by glatiramer acetate for 1,476 +/- 63 days
Number of subjects: 208
Study 11321192 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (oPBO and oGA)
Number of subjects: 208
Study 11321192 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (oGA)
Number of subjects: 208
Study 9396960 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release venlafaxine
Number of subjects: 20
Study 9396960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7648784 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin modified FSIVGTT (insulin infusion at 4 mUkg‐1.min‐1 from time 20 to 25 min)
Number of subjects: 10
Study 7648784 — intervention group
Group type: COMPARATOR
Intervention: Standard FSIVGTT (glucose infusion of 0.3 g/kg from time 0 to 2 min)
Number of subjects: 10
Study 2953752 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate administered daily for 4 weeks followed by concomitant hMG administration
Number of subjects: 0
Study 2953752 — intervention group
Group type: COMPARATOR
Intervention: Human menopausal gonadotropin (hMG) only
Number of subjects: 0
Study 31251544 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-density MFU-V treatments
Number of subjects: 91
Study 31251544 — intervention group
Group type: EXPERIMENTAL
Intervention: High-density MFU-V treatments
Number of subjects: 91
Study 31251544 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 91
Study 31251544 — intervention group
Group type: EXPERIMENTAL
Intervention: High-density MFU-V treatment
Number of subjects: 91
Study 31251544 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-assessment questionnaires
Number of subjects: 91
Study 29960200 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal diazepam plus transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 42
Study 29960200 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 42
Study 27068760 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-malarial treatment (specific dosage and duration not provided)
Number of subjects: 0
Study 27068760 — intervention group
Group type: EXPERIMENTAL
Intervention: Improving women's knowledge of malaria in pregnancy
Number of subjects: 0
Study 24558011 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot drink (paracetamol)
Number of subjects: 25